- United States
- /
- Logistics
- /
- NasdaqCM:JYD
Jayud Global Logistics Full Year 2024 Earnings: CN¥1.70 loss per share (vs CN¥3.47 loss in FY 2023)
Jayud Global Logistics (NASDAQ:JYD) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥565.3m (up 14% from FY 2023).
- Net loss: CN¥49.6m (loss narrowed by 32% from FY 2023).
- CN¥1.70 loss per share (improved from CN¥3.47 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jayud Global Logistics shares are down 14% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with Jayud Global Logistics.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:JYD
Jayud Global Logistics
Through its subsidiaries, provides a range of cross-border supply chain solution services worldwide.
Flawless balance sheet with slight risk.
Market Insights
Weekly Picks

Looking to be second time lucky with a game-changing new product

Second order memory play likely to double in a year

Intuitive Machines: To The Moon and Beyond!
AppLovin’s AI Engine Is Printing Profit
Recently Updated Narratives

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

A scaled, high-growth, franchise-driven beverage leader with strong penetration in China

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
